Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:AXSM News 31 December 2025 - 2 January 2026

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

NEW YORK, January 1, 2026, 21:06 ET — Market closed Axsome Therapeutics shares jumped 22.9% in the Dec. 31 session, ending at $182.64 after the company disclosed two U.S. FDA updates that put near-term regulatory milestones back in focus. The stock traded between $148.79 and $184.40 on the day, with about 3.1 million shares changing hands. The move matters because…
2 January 2026
····
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

NEW YORK, January 1, 2026, 16:58 ET — Market closed Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between…
1 January 2026
····
Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

NEW YORK, January 1, 2026, 13:41 ET — Market closed Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq The moves matter because regulatory calls can dominate small-cap biotech even when the broader healthcare sector…
1 January 2026
······
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing

Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing

NEW YORK, January 1, 2026, 07:18 ET — Market closed Key points: With U.S. markets closed on Thursday for the New Year’s Day holiday, Axsome Therapeutics shares were last up 22.9% at $182.64 after the company said the FDA granted priority review for its Alzheimer’s disease agitation filing. The stock swung between $148.79 and $184.40 in Wednesday’s session. Volume was…
1 January 2026
····
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

NEW YORK, January 1, 2026, 03:20 ET — Market closed Axsome Therapeutics Inc shares jumped 22.9% to $182.64 in Wednesday’s session, after touching $184.40, with about 3.1 million shares traded. The CNS drugmaker said the U.S. Food and Drug Administration accepted and granted priority review to its supplemental new drug application for AXS-05 (dextromethorphan-bupropion) — marketed as Auvelity for major…
1 January 2026
···
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation

Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation

NEW YORK, December 31, 2025, 19:19 ET — After-hours Axsome Therapeutics, Inc. shares jumped 22.9% to $182.64 in after-hours trading on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental New Drug Application for AXS-05 to treat agitation linked to Alzheimer’s disease and granted it Priority Review. The agency set an April 30, 2026 target…
1 January 2026
····
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

NEW YORK, December 31, 2025, 14:41 ET — Regular session Axsome Therapeutics shares jumped 23% in afternoon trading on Wednesday after the company said U.S. regulators accepted its application and granted a faster review for AXS-05 to treat agitation in Alzheimer’s disease. GlobeNewswire The FDA’s acceptance puts a hard deadline on the next major catalyst for Axsome, with an April…
31 December 2025
·····

Stock Market Today

  • Euronext Dublin GEM Notice Highlights Market Data Providers
    January 29, 2026, 4:07 AM EST. Euronext Dublin released a GEM notice outlining key market data providers including ICE Data Services and FactSet, both integral in supplying reference and market data. FactSet also provides the CUSIP Database used for securities identification, while SEC filings and related documents come via Quartr. TradingView supports broader market analytics. These contributors underpin transparency and data accuracy for market participants on Euronext Dublin's Growth Enterprise Market (GEM).
Go toTop